Mirati 849-010 - "KRYSTAL"

Gastrointestinal - KRYSTAL

Mirati 849-010 - "KRYSTAL"

Objective

Randomized Phase 3 Study of MRTX849 ['an orally-available, mutationselective small molecule covalent inhibitor of KRAS G12C] in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy

Principal Investigator(s)
Hugo Hool, MD

Clinical Trial Categories

  • UCLA Trio Clinical Trials